Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Income Statement [Abstract]        
Revenue $ 513
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 385
Research and development expenses (including non-cash share-based compensation expenses of $771, $1,688, $3,014 and $2,425, respectively) 1,445 2,167 5,018 4,017
General and administrative expenses (including non-cash share-based compensation expenses of $667, $1,500, $2,460 and $2,800, respectively) 1,352 2,221 5,248 5,170
Total operating costs and expenses 2,797 4,388 10,266 9,572
Loss from operations (2,797) (4,388) (10,266) (9,059)
Interest income 22 24 2
Net loss (2,775) (4,388) (10,242) (9,057)
Less: Net loss attributable to noncontrolling interest (29) (54) (123) (116)
Net loss attributable to common shareholders $ (2,746) $ (4,334) $ (10,119) $ (8,941)
Net loss per common share attributable to common shareholders:        
Basic and diluted $ (0.09) $ (0.14) $ (0.33) $ (0.32)
Weighted average common shares outstanding:        
Basic and diluted 30,451 30,455 30,244 28,090